ProShares Ultra Nasdaq Biotechnology is a ETF series of ProShares Trust (series S000018718). Net assets $73.7M as of 2026-05-31. Index fund.
Showing 15 of 200 holdings by value.
| Holding | Ticker | Value | % of fund |
|---|---|---|---|
| Total Return Swap | — | $5.4M | 735.46% |
| ProShares GENIUS Money Market ETF | — | $5.0M | 679.68% |
| Gilead Sciences, Inc. | — | $3.4M | 466.19% |
| Vertex Pharmaceuticals, Inc. | — | $3.4M | 465.27% |
| Amgen, Inc. | — | $3.3M | 448.26% |
| Total Return Swap | — | $2.9M | 394.23% |
| Total Return Swap | — | $2.4M | 326.34% |
| Regeneron Pharmaceuticals, Inc. | — | $2.4M | 320.53% |
| Total Return Swap | — | $1.9M | 262.08% |
| Alnylam Pharmaceuticals, Inc. | — | $1.5M | 201.07% |
| Revolution Medicines, Inc. | — | $1.2M | 156.64% |
| Biogen, Inc. | — | $1.1M | 144.37% |
| Repurchase Agreement | — | $945K | 128.25% |
| Illumina, Inc. | — | $921K | 125.08% |
| United Therapeutics Corp. | — | $902K | 122.47% |
| Report date | Net assets |
|---|---|
| 2026-05-31 | $73.7M |
| 2026-02-28 | $91.7M |
| 2025-11-30 | $87.7M |
| 2025-08-31 | $53.6M |
| 2025-05-31 | $44.3M |
| 2025-02-28 | $61.5M |
| 2024-11-30 | $77.5M |
| 2024-08-31 | $94.3M |